Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease - Takeaways - MDSpire

Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

  • By

  • Asmaa Mohamed Fteah

  • Doaa Mamdouh Aly

  • Mohamed A. Elrefaiy

  • Ali Abdel Rahim

  • April 13, 2026

  • 0 min

Share

  • 1

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disorder linked to obesity and insulin resistance.

  • 2

    GCKR gene variants, particularly rs1260326, influence hepatic glucose and lipid metabolism, contributing to MASLD risk.

  • 3

    FGF21 is a liver-derived hormone that mediates metabolic stress responses, with elevated levels indicating potential FGF21 resistance in MASLD.

  • 4

    This study investigates the combined effects of GCKR and FGF21 genetic variants on MASLD susceptibility and progression to metabolic dysfunction-associated steatohepatitis (MASH).

  • 5

    A total of 450 participants were analyzed, including MASLD, suspected MASH patients, and healthy controls, to assess genetic associations with liver disease.

Original Source(s)

Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

  • by Asmaa Mohamed Fteah, Doaa Mamdouh Aly, Mohamed A. Elrefaiy, Ali Abdel Rahim

  • April 13, 2026

Related Content

Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024)

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

Probiotic Effect on Quality of Life, Bowel Habits and Weight Loss after Different Types of Bariatric Surgeries, a Randomized Controlled Trial